Application of CST-14 in preparation of drug for treating osteoporosis

A technology of 1.CST-14, 2.CST-14, applied in the medical field, can solve the problems of patients' economic burden, small choice for patients, and few types of related drugs.

Active Publication Date: 2020-07-10
SHANDONG UNIV QILU HOSPITAL
View PDF4 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Clinically used RANKL antagonists come from bioengineering pharmaceuticals. There are few types of related drugs, and patients have little choice, and the cost of related drug synthesis is relatively high, causing economic burden to patients who need long-term application[2]
At the same time, the currently used bisphosphonate drugs have their own potential side effects[3], which to a certain extent affect the use of

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of CST-14 in preparation of drug for treating osteoporosis
  • Application of CST-14 in preparation of drug for treating osteoporosis
  • Application of CST-14 in preparation of drug for treating osteoporosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0030] Sources of experimental animals, reagents, culture media and buffers involved in the following examples:

[0031] CST-14 (purity 98.4%, CAS: 186901-48-4, its amino acid sequence is Pro-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Ser-Ser-Cys-Lys (Disulfide bridge :Cys2-Cys13)) (Gill Biochemical Co., Ltd.)

[0032] Wild-type BL6 / C57 female mice, CST knockout mice (T003038), OPG knockout mice (C57BL / 6N-Tnfr11bem1cyagen), RANKL transgenic rats (T002583) (Shandong University Animal Center)

[0033] PBS buffer, (Beiyuntian Biological Reagent Company)

[0034] Cathepsin K, RANK, RANKL antibodies (Santa Cruz Biotechnology, USA)

[0035] RIPA cell protein extraction lysate (Thermo Fisher, Pierce)

[0036] Protease Inhibitors (Beijing Solaibao Technology Co., Ltd.)

[0037] BCA protein quantification kit (Shanghai Yanxi Biotechnology Co., Ltd.)

[0038] Complete EDTA-Free (Roche Biopharmaceuticals)

[0039] Xylene (Sinopharm Chemical Reagent Co., Ltd.)

[0040] Neutral gum (Shangh...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
thicknessaaaaaaaaaa
Login to view more

Abstract

The invention discloses an application of a cyclic polypeptide CST-14 in preparation of a drug for treating osteoporosis. The CST-14 can be directly combined with a key receptor RANK in an osteoporosis process to antagonize an osteoclast induction function caused by RANKL and to play a protective role in the osteoporosis. An in vitro cell experiment result shows that the CST-14 can antagonize an osteoclast differentiation process caused by an osteoporosis key molecule RANKL. Meanwhile, an animal model shows that the CST-14 can inhibit the occurrence of the osteoporosis and improve disease conditions, does not have obvious toxic and side effects after long-term use, can be applied to the field of osteoporosis treatment and has broad application value and market prospect.

Description

technical field [0001] The invention relates to the field of medicine, in particular to the application of CST-14 in the preparation of medicines for treating osteoporosis. Background technique [0002] At present, osteoporosis is more common in clinical practice, and patients generally need long-term drug treatment. Among them, RANKL signaling system antagonist drugs, such as denosumab, are currently a class of drugs with definite therapeutic effects and potential application prospects[1] , are widely used all over the world. Clinically used RANKL antagonists come from bioengineering pharmaceuticals. There are few types of related drugs, and patients have little choice. Moreover, the cost of related drug synthesis is high, causing economic burden to patients who need long-term application [2]. At the same time, the currently used bisphosphonate drugs have their own potential side effects [3], which affect their use to a certain extent. As the key receptor of RANKL, RANK i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/12A61P19/10
CPCA61K38/12A61P19/10
Inventor 赵云鹏李魏玮邱成王文晗上官杨韬
Owner SHANDONG UNIV QILU HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap